Interesting. Supports Trof being priced at a similar level of $350k+ you'd think. And helps to reinforce that Trof approval must be all but impossible not to occur.
- Forums
- ASX - By Stock
- NEU
- Ann: Rett Syndrome NDA accepted for Priority Review by FDA
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.71%
!
$13.07

Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-157
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.07 |
Change
0.220(1.71%) |
Mkt cap ! $1.635B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.880M | 371.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 157 | $13.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.08 | 1355 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 631 | 13.080 |
8 | 672 | 13.070 |
6 | 660 | 13.060 |
10 | 1471 | 13.050 |
5 | 1486 | 13.040 |
Price($) | Vol. | No. |
---|---|---|
13.090 | 1268 | 3 |
13.100 | 1512 | 13 |
13.110 | 1027 | 11 |
13.120 | 1606 | 10 |
13.130 | 1403 | 5 |
Last trade - 13.16pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CDE
CODEIFAI LIMITED
John Houston / Martin Ross, Executive Chairman / COO
John Houston / Martin Ross
Executive Chairman / COO
Previous Video
Next Video
SPONSORED BY The Market Online